Copy to clipboard 
Next Science reports that XPERIENCE No Rinse Solution has been shown to have persistent efficacy against the formation of planktonic bacteria and bacterial biofilms. The results were reported in a new study published in The Journal of Arthroplasty.
The study, which looked at total hip replacement procedures, also found that XPERIENCE produced minimal cytotoxic effects to human tissue, allowing the solution to remain in the body without the need for a subsequent rinse. Additionally, XPERIENCE – cleared by FDA for U.S. sale in 2021 – was shown to inhibit biofilm formation for up to five hours after application.
Infection prevention, detection and reduction are growing concerns among orthopedic surgeons and orthopedic companies.
According to a study published in 2021, prosthetic joint infection (PJI) remains a significant burden in total hip and knee replacement in the U.S. Estimates indicate that, by 2030, the annual hospital costs related to PJI of the hip and knee will be $1.85 billion. Interventions to reduce or prevent the occurrence of PJI continue to be at the forefront of research efforts and commercial development.
Next Science’s study also found that XPERIENCE showed higher in vitro antimicrobial efficacy than three other commercially available adjuvants. The comparative treatments each reduced biofilm in all bacterial strains tested by approximately 1-log or less when the application times in their respective instructions for use were followed. However, XPERIENCE reduced biofilm by approximately 3-log to 8-log when used as directed.
